Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL

Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL

Abstract: CD19-directed chimeric antigen receptor–engineered (CAR) T-cell therapy elicits high response rates but fails to induce durable responses in most adults with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). In a previous clinical trial, we observed anti-CAR immune...

Full description

Saved in:
Bibliographic Details
Main Authors: Jordan Gauthier, Emily C. Liang, Jennifer J. Huang, Erik L. Kimble, Alexandre V. Hirayama, Salvatore Fiorenza, Jenna M. Voutsinas, Qian (Vicky) Wu, Carla A. Jaeger-Ruckstuhl, Barbara S. Pender, Delaney R. Kirchmeier, Aiko Torkelson, Kristina Braathen, Ryan Basom, Mazyar Shadman, Noam E. Kopmar, Ryan D. Cassaday, Stanley R. Riddell, David G. Maloney, Cameron J. Turtle
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952925000291
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2473952925000291

Similar Items